JMP Securities upgraded Sabra Health Care (SBRA) to Outperform from Market Perform with a $20 price target The firm expects “multiple tailwinds to result in outsized returns” for the stock.
I created Within This Party as a graduation project in 2022. The world was not much better back then, than it is today. Although perhaps on the surface, it was brighter. But there was darkness in ...
Jefferies lowered the firm’s price target on Sabra Health Care to $20 from $21 and keeps a Buy rating on the shares as part of a 2025 outlook. Within healthcare real estate investment trusts ...
On Dec. 5, Mizuho analyst Vikram Malhotra downgraded the rating for Sabra Health Care REIT from Outperform to Neutral and maintained the price target of $20. On Oct. 31, Sabra Health Care REIT ...
An easing of conditions in the retrocession market has helped to bolster capacity in advance of the January 1st 2025 reinsurance renewals, resulting in a situation where capital was more than ...